Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
Explore this paper's citation graph
Summary
The bezafibrate-lovastatin combination is a possible therapeutic option for severe, resistant FCHL, but close medical supervision is needed because of potential side effects.
- Type
- article
- Published
- 1993-03-01
- Cited by
- 13
- References
- 0
- OpenAlex
- https://openalex.org/W23750298
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:11341222
Keywords
Bezafibrate, Lovastatin, Medicine, Internal medicine, Hyperlipidemia
References
No references recorded for this paper.
Cited by
- Combined Treatment with Pravastatin and Gemfibrozil in Patients with Refractory Familial Combined Hyperlipidaemia
- Diagnostyka i leczenia aterogennej dyslipidemii
- Die Kardiologie auf dem Weg in das nächste Jahrtausend
- Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
- Role of fibrates in the management of hypertriglyceridemia.
- Pilot Study of the Effect of the Simvastatin-Ciprofibrate Combination on Myocardial Infarction Risk Profile in Patients with Refractory Familial Combined Hyperlipidaemia
- Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
- Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy.
- The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia: a review of fluvastatin
- Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
- Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
- Statin—Fibrate Combination Therapy
- National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
- References
Related papers
- Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency.
- The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy.
- Reciprocal Changes of Plasma Apo AI and Apo E Levels in Streptozotocin-Induced Diabetic Rats
- Lipoproteins and Apolipoproteins in Young Nonobese Arab Women With NIDDM Treated With Insulin
- Deterioration of the metabolic risk profile in women. Respective contributions of impaired glucose tolerance and visceral fat accumulation.
- Management of primary mixed hyperlipidemia with lovastatin.